{
    "nctId": "NCT02874092",
    "officialTitle": "Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis",
    "inclusionCriteria": "RA cohort\n\n* Receiving MTX at stable doses of 10 to 25 mg weekly for at least 12 weeks\n* Have a DAS28 of 3.2 or higher (The level of disease activity is considered to be low if the DAS28 is 3.2 or less) (Prevoo et al., 1995)\n\nOA cohort\n\n* Diagnosis of osteoarthritis made by physician.\n* Must have minimum age of 18 Years",
    "exclusionCriteria": "RA cohort\n\n* History of sensitivity to study medications or any of their excipients\n* Previous intolerance to MTX\n* Current treatment with antiplatelet therapy\n* Absolute indication for anti-platelet therapy\n* Need for chronic oral anticoagulant therapy\n* Severe hepatic impairment (eg, ascites and/or clinical signs of coagulopathy)\n* Renal failure (eGFR \\<30 or requiring dialysis)\n* A known bleeding diathesis, hemostatic or coagulation disorder, or prior major bleeding\n* Prior stroke\n* Active pathological bleeding\n* History of intracranial haemorrhage\n* Life expectancy \\<12 months based on investigator's judgement\n* Patients considered to be at risk of bradycardic events (e.g., known sick sinus syndrome or second or third degree atrioventricular \\[AV)\\] block) unless already treated with a permanent pacemaker\n* Anemia (hematocrit \\< 27%)\n* Platelet count \\< 100,000/ml\n* Concomitant use of strong CYP 3A inhibitors or inducers\n* History of thrombocytopenia or neutropenia\n* Pregnant or nursing women, or females with a positive pregnancy test at screening\n* Females of child bearing potential not using acceptable method of birth control prior to or during study\n* Concern for inability of the patient to comply with study procedures and/or follow up (eg, alcohol or drug abuse)\n\nOA cohort:\n\n* History of sensitivity to study medications or any of their excipients\n* Current treatment with antiplatelet therapy\n* Absolute indication for anti-platelet therapy\n* Need for chronic oral anticoagulant therapy\n* Severe hepatic impairment (eg, ascites and/or clinical signs of coagulopathy)\n* Renal failure (eGFR \\<30 or requiring dialysis)\n* A known bleeding diathesis, hemostatic or coagulation disorder, or prior major bleeding\n* Prior stroke\n* Active pathological bleeding\n* History of intracranial haemorrhage\n* Life expectancy \\<12 months based on investigator's judgement\n* Anemia (hematocrit \\< 27%)\n* Platelet count \\< 100,000/ml\n* History of thrombocytopenia or neutropenia\n* Pregnant or nursing women, or females with a positive pregnancy test at screening\n* Females of child bearing potential not using acceptable method of birth control prior to or during study\n* Concern for inability of the patient to comply with study procedures and/or follow up (eg, alcohol or drug abuse)"
}